Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements (Details)

v3.22.1
Collaboration and License Agreements (Details)
1 Months Ended 12 Months Ended
Mar. 10, 2020
USD ($)
Jul. 31, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
Country
Milestone
BioSense License and Assignments Agreement [Member]      
Collaboration and License Agreement [Abstract]      
Upfront payment received $ 1,650,000    
Milestone payment achieved for performance obligation, recorded as collaboration revenue     $ 100,000
Milestone payments received     0
Maximum amount of payments receivable for development, regulatory and commercial milestones     84,500,000
BioSense License and Assignments Agreement [Member] | Rexahn [Member]      
Collaboration and License Agreement [Abstract]      
Upfront payment received $ 1,550,000    
Processa License Agreement [Member]      
Collaboration and License Agreement [Abstract]      
Upfront payment received   $ 200,000  
Milestone payments received     $ 0
Upfront payment received in common shares (in shares) | shares   44,689  
Upfront payment received in common shares   $ 289,000  
Period of restriction from selling common stock     1 year
Number of times sales milestone payments | Milestone     1
Percentage of milestone payments eligible to receive on sub-license agreement     32.00%
Number of countries | Country     1
Milestone period to administer drug clinical trial of licensed product on first patient     3 years
Milestone period to administer drug clinical trial of licensed product on first patient for second indication     5 years
Period of opportunity to cure breach of agreement     120 days
Period of prior written notice to be served for termination of agreements     120 days